Biopharmaceutical company Hansa Medical AB (STO:HMED) reported on Wednesday net loss of SEK176.6m, or SEK4.97 per share, for 2017, from January 2017 to December 2017.

This was a decline over net loss of SEK111.13m, or SEK3.37 per share, in 2016.

Net revenues for the year were SEK3,442,000, as compared with SEK2.579m in 2016.

Hansa Medical is developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead product, IdeS, is a proprietary antibody-degrading enzyme currently in late-stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and in acute autoimmune indications.

(EUR1.00=SEK9.9)